Tilos Therapeutics Appoints Detlev Biniszkiewicz, Ph.D. as Independent Director

CAMBRIDGE, Mass., March 19, 2018 – Tilos Therapeutics, a biopharmaceutical company developing anti-LAP antibodies for the treatment of cancer, fibrosis and autoimmune diseases, today announced the appointment of Detlev Biniszkiewicz as Independent Director.

“Detlev brings broad strategic insight into both immuno-oncology drug development and company creation,” said Barbara Fox, Ph.D., founder and Chief Executive Officer of Tilos. “His deep understanding of the field from both a scientific and business perspective will be invaluable to Tilos as we build our anti-LAP antibodies into foundational assets in immuno-oncology.”

“I am excited to be joining Tilos at this critical inflection point in the company’s growth. I was drawn to Tilos’s strong team and to the company’s novel approach to modulating the tumor microenvironment through LAP, the latency-associated peptide of TGFβ. Immuno-oncology is a dynamic field, and I look forward to helping build a successful company that can bring new medications to patients in need ” said Dr. Biniszkiewicz.

Dr. Biniszkiewicz is an experienced biopharma executive with deep knowledge of oncology and immuno-oncology. He is past-President and CEO of Surface Oncology (SURF), where he led its growth and transformation through to clinical-stage and its preparation for a public offering. Prior to Surface Oncology, he was Vice President of Strategy in AstraZeneca’s Oncology Unit and was part of the oncology leadership that developed Lynparza® and Tagrisso® – two innovative medicines that help thousands of patients suffering from cancer. His group transformed AstraZeneca’s Oncology pipeline through numerous licensing deals, clinical alliances, and academic collaborations. Dr. Biniszkiewicz has also held multiple roles at Novartis including Global Head of Portfolio Management and Analysis, where his group provided oversight of Novartis’ research and early development portfolio. He began his career as a Principal at the Boston Consulting Group (BCG) and performed his academic research with Dr. Rudolf Jaenisch at the Whitehead Institute at the Massachusetts Institute of Technology in Cambridge, MA.

About Tilos Therapeutics
Tilos Therapeutics is developing anti-LAP antibodies, an innovative approach that targets the central control point for TGFβ activation for the treatment of cancer, fibrosis and autoimmune diseases. Anti-LAP antibodies have the potential to transform the immunosuppressive tumor microenvironment and mitigate resistance to checkpoint inhibitors with a novel mechanism of action that inhibits TGFβ release and reduces immunosuppressive cell populations. The Company’s approach builds on decades of work by its scientific founders at Brigham and Women’s Hospital in understanding the role of LAP-expressing cells in immune regulation. Tilos was founded in 2016 with funding from Boehringer Ingelheim Venture Fund, Partners Innovation Fund and ShangPharma Innovation Fund. 

Media Contact
MacDougall Biomedical Communications
Amanda Houlihan
ahoulihan@macbiocom.com or
Kari Watson
kwatson@macbiocom.com
 

781-235-3060